MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.…
MDxHealth S.A. Q3 2026 Earnings Call Summary
MDxHealth (NASDAQ: MDXH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 364 employees.
The shares were at 0.1074 USD on 20 November 2026, down 97.4% over 52 weeks. Its 52-week range is 0.1012 USD to 4.350 USD: the price is 97.5% below the high and 6.1% above the low.
Its market capitalisation is 10.25M USD.
MDxHealth reports return on equity of 277.2%, an operating margin of -22.1% and revenue down 17.2% year over year.
Its debt exceeds its cash by 73.88M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 25 February 2027.